| HRA011076
(Controlled Access)
|
Pulmonary fibrosis (PF) following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a life-threatening complication, characterized by irreversible respiratory dysfunction. Despite growing concerns about PF after SARS-CoV-2 infection, early recognition remains challenging. Additionally, the role of changes in respiratory and intestinal microbiota in PF progression remains insufficiently understood. This study employs a multi-omics approach to investigate alterations in both microbiota profiles and clinical indicators in patients with PF following SARS-CoV-2 infection. The aim is to develop a predictive model for the onset and progression of PF, incorporating risk stratification to enable early targeted therapeutic interventions and facilitate timely clinical decision-making, ultimately mitigating irreversible parenchymal remodeling and improving long-term respiratory outcomes. |
